AllDocs -> cancers

l del file contenuto in http://sweb.uky.edu/~idacev0/mpa2003.ppt . G o o g l e crea automaticamente la versione .html dei documenti durante la scansione del Web. Per inserire un segnalibro o un collegamento alla pagina, utilizzare il seguente URL: http://www.google.com/search?q=cache:S6v91KsXioAJ:sweb.uky.edu/~idacev0/mpa2003.ppt+allintitle:+ovarian+cancer+filetype:pdf+OR++filetype:doc+OR+filetype:ppt+OR++filetype:xls+OR+filetype:rtf&hl=it&lr=lang_en Google non è collegato agli autori di questa pagina e non è responsabile del suo contenuto. I termini specificati sono presenti solamente in collegamenti che rimandano alla seguente pagina: allintitle ovarian cancer Significant between-group differences were found only on the SOS ( =.164, p=.042), ICIAI Ethnic Group Behaviors scale ( =.205, p=.014), and ICIAI Ethnic Group Principles scale ( =.269, p=.001). ...

~ 5K-Run / 3K-Walk ~ Co-Ed Softball Tournament ~ Co-Ed Volleyball Tournament ~ Children’s Entertainment ~ Food, Drinks, & Door Prizes ~ Ovarian Cancer Education April 10, 2004 Kiwanis Island Park Merritt Island, Florida 3rd Annual Event S andi C hilders C orporate S ponsors AllStar Corporate Media, Inc. Brevard Mutual Insurance Boeing Florida Employee Community Fund Bussen-Mayer Engineering Group Coldwell Banker US 1 Area Realty Cowling Eye Care Georgiana United Methodist Church Jacobs Sverdrup National Awakenings Magazine Safe Harbor Financial Services United Space Alliance The NOCC is a nonprofit organization whose mission is to raise awareness about ovarian cancer and to promote education about this disease. By dispelling myths and misunderstandings, ...

ovarian cancer OVARIAN CANCER STUDY (NSGO-OC-0303) Phase II study on Carboplatin-Taxotere in relapsing ovarian cancer CLINICAL / RADIOLOGICAL EVALUATION FORM Please complete this form after each evaluation. To be sent every 9 weeks to: NSGO data center, Kløvervænget 10,5, Odense University Hospital, DK-5000 Odense C. Denmark sequential ident.no. patient initials date of birth GIVEN AT REGISTRATION CAPITAL LETTERS First-middle-last D D M M Y Y |__|__|__|__|__|__| |__|__|__| |__|__|__|__|__|__| INSTITUTION:-------------------------------NO: |__|__| RESPONSIBLE PHYSICIAN: ...

To find out more about ovarian cancer go to http://ovariancancer.jhmi.edu It is time we stop the loss of mothers, sisters, daughters, wives and girlfriends from ovarian cancer so I have decided to do something about it. On September 16-19, 2004, I will be climbing in the HERA Ovarian Cancer Climb for Life. I will be climbing in recognition of my friend Sean Patrick who has been fighting this disease for 7 years and for all of the women battling this disease and the 25,500 women who will be newly diagnosed this year. Can I count on your support? The money raised will go directly to support research for early detection of ovarian cancer and new directions in treatment and to aide women and their families battling this disease as well as to support awareness and wellness programs. On the research front, our most pressing task is to develop a reliable early detection test for ovarian cancer ...

MAT 117 An application of Bayes’ Theorem to Medical Testing: page 1 of 2 Prof. Shaver Screening for Ovarian Cancer Screens Fail A June 2002 news report in Scientific American magazine 1 began with the provocative line, “ Cancer screening is notoriously unreliable: a positive result often does not indicate disease, and a negative result does not always mean the patient can walk away with a handshake and a smile.” The article went on to report of a new blood test for ovarian cancer , a cancer which is almost invariably fatal unless caught at a very early stage. This test is able to detect ovarian cancer in every single case. Nevertheless, the author says, “[] surprisingly, the ability to find all cases of cancer is not the best way to judge the value of a screening test.” A later letter to the editor 2 attempted to clarify. Granting the accuracy ...

19 Jul 2003 No. 55 H I G H L I G H T S Paclitaxel beneficial in platinum-sensitive relapsed ovarian cancer 7 Advances in the treatment of advanced Hodgkin’s disease 8 CONTENTS ABT 510 may be safe, have antitumour activity 4 Advances in treatment of advanced Hodgkin’s disease 8 Anthracyclines: increased risk of AML 10 Apaziquone may be effective for bladder cancer 4 Aromatase inhibitors promising in breast cancer 3 Bortezomib: responses in relapsed refractory myeloma 7 Breast, colorectal cancer : UK NICE releases guidance on therapy 4 CAM use common in localised prostate cancer 9 Chemoprevention with COX-2 inhibitors too costly 9 Cisplatin + IFN- a + fluorouracil in advanced liver cancer 7 CV disease: complication of testicular ...

continued on back Ovarian cancer is the rapid growth of abnormal cells in the ovaries of the female reproductive system. The ovaries are the two small egg-filled sacs on each side of the uterus which produce estrogen and play a key role in conception and menstruation. Cancer can occur in one or both ovaries. When there is a malignancy, the ovaries typically enlarge, and cancer cells may fall off the ovary’s surface and implant themselves throughout the abdominal cavity. Each one of these seedlings can then grow into a separate ovarian cancer tumor nodule. Who is at risk for ovarian cancer ? Each year, more than 20,000 American women will be diagnosed with ovarian cancer . The disease most often affects post- menopausal women, although women of any age may develop it. While scientists have not uncovered the cause, women ...

[ CANCER RESEARCH 62, 1266 –1270, March 1, 2002] Advances in Brief Treatment of Ovarian Cancer with a Tropism Modified Oncolytic Adenovirus 1 Gerd J. Bauerschmitz, John T. Lam, Anna Kanerva, Kaori Suzuki, Dirk M. Nettelbeck, Igor Dmitriev, Victor Krasnykh, Galina V. Mikheeva, Mack N. Barnes, Ronald D. Alvarez, Peter Dall, Ramon Alemany, David T. Curiel, and Akseli Hemminki 2 Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery [G. J. B., J. T. L., A. K., K. S., D. M. N., I. D., V. K., R. D. A., D. T. C., A. H.] and Division of Gynecology Oncology, Department of Obstetrics and Gynecology [M. N. B., R. D. A.], University of Alabama at Birmingham, Birmingham, Alabama 35294-3300; VectorLogics, Inc., Birmingham, Alabama 35233 [V. K., G. V. M.]; Duesseldorf University Medical Center, Department of Obstetrics and Gynecology, Heinrich-Heine University, ...

ovarian cancer WVU Puts Idle Computers to Work Against Ovarian Cancer Researchers at West Virginia University's Mary Babb Randolph Cancer Center and Parabon Computation, Inc., a leading distributed computing company, announced today a breakthrough discovery about one of the deadliest types of ovarian cancer - clear cell carcinoma. Some cancers, like clear cell carcinoma, are resistant to chemotherapy treatments. To better understand how this resistance takes place, Cancer Center scientists developed databases of certain genes within ovarian cancer tissues. From this data, they studied DNA repair genes, which control whether or not a tumor will respond to chemotherapy. Two of these genes were ERCC1 and XPB. Parabon analyzed the data, using state-of-the-art statistical techniques and the massive computing resources available from the company's distributed computing solution, ...

CYP17 PROMOTOR POLYMORPHISM AND OVARIAN CANCER RISK Amanda B. S PURDLE 1 *, Xiaoqing C HEN 1 , Mohammed A BBAZADEGAN 2 , Nicholas M ARTIN 3 , Soo-Keat K HOO 4 , Terry H URST 4 , Bruce W ARD 4 , Penelope M. W EBB 5 , Georgia C HENEVIX -T RENCH 1 1 Cancer Unit, Joint Experimental Oncology Programme, The Queensland Institute of Medical Research and The University of Queensland, Brisbane, Queensland, Australia 2 Institute for Molecular and Human Genetics, Georgetown University Medical Center, Washington D.C., USA 3 Epidemiology Unit, The Queensland Institute of Medical Research and The University of Queensland, Brisbane, Queensland, Australia ...

OVARIAN CANCER CLASSIFICATION WITH MISSING DATA Christian Renz * , Jagath C. Rajapakse School of Computer Engineering Nanyang Technological University Singapore 639798 crenz@web42.com, asjagath@ntu.edu.sg Khalil Razvi, Stephen Koh Chee Liang Department of Obstetrics & Gynaecology National University of Singapore Singapore 119260 khalilrazvi@nus.edu.sg, obgkohcl@nus.edu.sg ABSTRACT Unlike for other types of cancers, there are no tests suit- able for mass screening that will reliably detect cases of ovarian cancer . The most commonly used test in clinical environments is the test for the tumour marker CA 125, with an accuracy of only up to 70%. Research so far has mostly focused on predicting the risk of malignancy of pelvic masses, using operator-dependent ultrasound charac- teristics. In this paper, we examine the use of standardized ...

The RAGs Software: Genetic Risk Assessment Guidelines for Breast/ Ovarian and Colorectal Cancer Jon Emery, 1999 General Practice and Primary Care Research Unit, Department of Public Health and Primary Care, University of Cambridge, Institute of Public Health, Forvie Site, Robinson Way, Cambridge CB2 2SR, United Kingdom. Email: jde10@medschl.cam.ac.uk IMPORTANT INFORMATION The breast/ ovarian and colorectal guidelines below were designed as demonstration guidelines to test the RAGs ( R isk A ssessment in G enetic s ) software. They are presented here for information purposes only, to supplement the paper by Coulson et al. (2001) “RAGs: A Novel Approach to Computerized Genetic Risk Assessment and Decision Support from Pedigrees” in Methods of Information In Medicine . Unlike official published guidelines, the protocols below have not received professional ...

KERBRAT P. et al. Electronic Journal of Oncology , 2001, 1 , 32-42 __ © FNCLCC, 2001 Standards, Options and Recommendations: Ovarian cancer P. KERBRAT 1 , C. LHOMMÉ 2 , B. FERVERS 3, 4 , J.P. GUASTALLA 3 , L. THOMAS 5 , N. TOURNEMAINE 6 , J.P. BASUYAU 7 , C. COHEN-SOLAL 8 , P. DUVILLARD 2 , T. BACHELOT 3 , I. RAY 3 , E. VOOG 3 AND J. DAUPLAT 9 1 Centre Eugène Marquis, Rennes 2 Institut Gustave Roussy, Villejuif 3 Centre Léon Bérard, Lyon 4 FNCLCC, Paris 5 Institut Bergonié, Bordeaux 6 ...

Kiwanis Island Pavilion Turn Lane Merritt Avenue SR 520 Eastbound (Northern most lane only) Sykes Creek Parkway (eastern most lane) NORTH Walk Turnaround Point X Run Turnaround Point Start/Finish Line Sandi Childers Ovarian Cancer Awareness Benefit - 5K-Run/3K-Walk Road Course John Hurdle Bridge

ACUTE LEUKEMIA AFTER THERAPY WITH ALKYLATING AGENTS FOR OVARIAN CANCER A Study of Five Randomized Clinical Trials M ARK H. G REENE , M. D., J OHN D. JR., SC. D., E. G REER , M. D., J OHN A. B LESSING , PH. D., AND A LON Abstract We evaluated the occurrence of acute leukemia (ANL) among 1399 women with ovarian cancer who were treated in five randomized clinical trials. Of the 1399 women, 998 had been treated with ing agents, and among these, 12 cases of ANL were observed; the expected number was 0.11. Ten patients with ANL had received and two ANL was not observed in 401 women who had been treated with surgery or radiation or both, without agents. The excess risk of ANL that was asso- ciated with alkylating-agent ...

Anaheim, CA 92807 1-800-222-9880 1268 N. Lakeview Ave. TECO DIAGNOSTICS CA 125 ( MICROTITER ASSAY ) Enzyme Immunoassay for the Quantitative Determination of Ovarian Cancer Antigen CA125 in Human Serum F OR IN VITRO D IAGNOSTIC U SE O NLY Store at 2 to 8 ° C. P ROPRIETARY AND C OMMON N AMES CA125 Enzyme Immunoassay I NTENDED U SE For the quantitative determination of the Cancer Antigen CA125 concentration in human serum. I NTRODUCTION Cancer Antigen 125 (CA125) is a surface antigen associated with epithelial ovarian cancer . In serum, CA125 is associated with a high molecular weight glycoprotein. Published studies ...

H:\EVERYONE\SYSTEMIC\Chemo\Protocol\Gyne\GOBEP.doc GOBEP Page 1 of 4 BCCA Protocol Summary for Non-dysgerminomatous Ovarian Germ Cell Cancer Using Bleomycin, Etoposide, and Cisplatin Protocol Code GOBEP Tumour Group Gynecology Contact Physician Dr. Ken Swenerton ELIGIBILITY: • non-dysgerminomatous ovarian germ cell cancer • as an adjuvant, or for patients with low, intermediate or high risk according to the international consensus prognostic classification (based upon the more frequent experience with analgous testicular tumours). Adjuvant Criteria: Retroperitoneal lymph node dissection pathology demonstrating involvement estimated to be associated with > 50% risk of subsequent relapse: 5 or more nodes involved, any involved node greater than or equal to 2 centimeters in diameter, or involved lymph node with extracapsular ...

Copyright © 1998 by W.B. Saunders Company. All rights reserved. 342 A BASIC INFORMATION DESCRIPTION A malignant growth in the ovary that is likely to spread to other body parts and threaten life. It affects females of all ages but is most common after age 50. There are many dif- ferent types of ovarian cancer . Epithelial tumors account for the majority and are the most aggressive. Other ovarian cancers are slow growing or metastasized from other can- cers in the body. FREQUENT SIGNS AND SYMPTOMS Frequently no symptoms occur until the tumor becomes large. The earliest symptoms include: • Vague discomfort in the lower abdomen. • Gastrointestinal upsets. • Irregular menstrual periods. Later symptoms: • Deep voice. • Excessive hair growth. • Unexplained weight loss. • An enlarged, hard and sometimes tender mass in ...